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T cell receptor (TCR) signaling without CD28 can
elicit primary effector T cells, but memory T cells
generated during this process are anergic, failing to
respond to secondary antigen exposure. We show
that, upon T cell activation, CD28 transiently pro-
motes expression of carnitine palmitoyltransferase
1a (Cpt1a), an enzyme that facilitates mitochondrial
fatty acid oxidation (FAO), before the first cell divi-
sion, coinciding with mitochondrial elongation and
enhanced spare respiratory capacity (SRC). micro-
RNA-33 (miR33), a target of thioredoxin-interacting
protein (TXNIP), attenuates Cpt1a expression in the
absence of CD28, resulting in cells that thereafter
are metabolically compromised during reactivation
or periods of increased bioenergetic demand. Early
CD28-dependent mitochondrial engagement is
needed for T cells to remodel cristae, develop SRC,
and rapidly produce cytokines upon restimulation—
cardinal features of protective memory T cells.
Our data show that initial CD28 signals during T cell
activation prime mitochondria with latent metabolic
capacity that is essential for future T cell responses.INTRODUCTION
CD28 is the receptor for B7 molecules (CD80 and CD86), which
are expressed on activated antigen presenting cells, and pro-vide essential signals for full T cell activation. Over the years,
it has become clear that CD28 signals do not act solely to
amplify T cell receptor (TCR) signaling, but control a wide range
of processes, including the cell cycle, epigenetic modifications,
metabolism, and post-translational modifications (Esensten
et al., 2016). Nevertheless, a complete understanding of the
biology of CD28 is lacking. Because CD28 and its family mem-
bers are targets of current and developing immunotherapies,
understanding how these accessory receptors regulate T cell
function is of broad interest and clinical importance (Esensten
et al., 2016).
A prevailing model in immunology is that CD28 promotes the
glycolytic flux needed for full effector T (TE) cell activation, dif-
ferentiation, and proliferation (Frauwirth et al., 2002; Jacobs
et al., 2008; MacIver et al., 2013). However, in vivo, T cells
do not always require this initial CD28 costimulation to mount
primary responses or to form long-lasting antigen-specific
T cells but need it specifically to develop into protective mem-
ory (TM) cells, which ‘‘remember’’ past infections and respond
robustly to secondary antigen challenge (Borowski et al.,
2007; Ku¨ndig et al., 1996; Mittru¨cker et al., 2001; Villegas
et al., 1999). How initial CD28 signals contribute to the genera-
tion of protective TM cells remains unclear. We have shown that
long-lived TM cells utilize fatty acid oxidation (FAO) and main-
tain fused mitochondria with tight cristae and spare respiratory
capacity (SRC) (Buck et al., 2016; van der Windt et al., 2012),
the reserve energy generating capacity in the mitochondria
beyond the basal state. This metabolic phenotype facilitates
their rapid recall function (van der Windt et al., 2013). We there-
fore speculated that CD28 primes mitochondria during the
initial phase of T cell activation with the metabolic capacity
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RESULTS
CD28 Costimulation Endows T Cells with Latent
Mitochondrial Respiratory Capacity
We activated CD8+ naive T (TN) cells with aCD3 in the presence
(+) or absence () of aCD28 (Figure 1A) and 8 hr later exposed
them to oligomycin, an ATP synthase inhibitor, and carbonyl cy-
anide-4-(trifluoromethoxy)phenylhydrazone (FCCP), a protono-
phore that dissipates the mitochondrial H+ gradient and
uncouples oxygen consumption from ATP production. FCCP re-
veals the maximal respiratory capacity as cells consume oxygen
(measured as oxygen consumption rate [OCR]) in an attempt to
re-establish the H+ gradient. Cells primed (+) aCD28 had an
increased extracellular acidification rate (ECAR, indicates aero-
bic glycolysis) after oligomycin (indicating their glycolytic reserve
[GR]) (Figure 1A), and increased uptake of 2-NBDG (Figure S1A),
highlighting enhanced glycolysis in cells primed (+) aCD28 (Frau-
wirth et al., 2002; Jacobs et al., 2008; MacIver et al., 2013). How-
ever, CD28 signals also endowed cells with significant SRC,
measured as the difference between basal OCR (indicates
oxidative phosphorylation [OXPHOS]) and maximal OCR after
FCCP (Figures 1A and S1B). This early SRC was absent in
T cells primed () aCD28, indicating that mitochondria in these
cells were operating close to their bioenergetic limit. In keeping
with similar basal OCR 8 hr after activation (Figure S1B), these
cells had equal ATP levels in the basal state (Figure S1C).
We assessed T cells differentiated toward the TM phenotype in
interleukin (IL)-15 (IL-15 TM) (Figure 1B) and found that IL-15 TM
cells primed (+) aCD28 had significant SRC, while the lack of
SRC evident 8 hr after activation (Figures 1A and S1B) persisted
in cells primed () aCD28 (Figure 1B), despite normal TM cell
marker expression and survival (Figures S1D and S1E). Ex vivo
TM cells from uninfected CD80/86
/ mice, which lack these li-
gands for CD28 and thus provide a costimulation-deficient envi-
ronment, also displayed decreased SRC (Figures 1C and 1D).
Furthermore, restimulated TM cells derived from TN cells primed
(+) aCD28 increased OCR and exhibited marked SRC (z200%
of basal OCR) (Figure 1E) and GR (Figure S1F). However, IL-15
TM cells primed () aCD28 had diminished basal OCR that did
not rise upon restimulation and had neither SRC (Figure 1E)
nor GR (Figure S1F). IFN-g production in IL-15 TM cells primedFigure 1. CD28 Costimulation Endows T Cells with Latent Mitochondr
Naive CD8+ T cells were activated with bead- or plate-bound aCD3 (5 mg/mL), IL
(A) Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) we
extracellular flux analyzer (EFA). Glycolytic reserve (GR) and spare respiratory ca
(B) 3 days after activation, cells were switched to IL-15 for 3 days to generate TM c
OCR 3 100%).
(C) CD8+ TM cells (CD44
hi/CD62Lhi) were sorted from spleens and lymph nodes of
was assayed after consecutive injections of oligo, FCCP, and rotenone and antim
(D) SRC of the graphs in (C) was calculated.
(E) IL-15 TM cells generated as in (B) were restimulated with aCD3/28 beads an
sequential treatment with oligo, FCCP, and R+A.
(F) IL-15 TM cells were restimulated and intracellular IFN-g was assessed by flow
(G) TE cells were switched to 10 mM (upper panels) or 0.3 mM glucose (AGR, acut
and the maximal respiration rate was measured after FCCP.
(H) SRC was determined as in (A).
Data shown as mean ± SEM, representative ofR3 separate experiments. Statist
Student’s t test, *p < 0.05; **p < 0.01; ***p < 0.001.
See also Figure S1.() aCD28 was also reduced (Figure 1F). Together, these data
indicate that TM cells generated without costimulation are meta-
bolically and functionally impaired.
Initial CD28 signals imparted long-lasting mitochondrial SRC,
and we questioned whether this could be detected in CD8+ TE
cells (IL-2 TE), which do not require OXPHOS for energy if suffi-
cient glucose and IL-2 are present for aerobic glycolysis (Chang
et al., 2015; Sena et al., 2013). IL-2 TE cells primed ± aCD28 had
no differences in basal ECAR or OCR (before or after FCCP)
when in 10 mM glucose (Figure 1G). When cells were forced to
use mitochondrial-derived ATP by acute glucose-restriction
(AGR), ECAR was diminished equivalently in cells generated ±
aCD28 (Figure 1G). However, IL-2 TE primed () aCD28 cells
placed under AGR failed to enhance OCR after oligomycin/
FCCP (Figures 1G and S1G), revealing their lack of SRC (Figures
1H and S1H). Survival of the cells under AGR was unaffected at
this time point (Figure S1I). SRC became evident in IL-2 TE cells
primed (+) aCD28 under AGR (Figures 1G and 1H), indicating
that CD28 signals during activation endow T cells with latent
SRC. Increased TCR signal strength could not compensate for
the absence of CD28 costimulation during activation, nor was
TCR expression altered, but increased aCD28 promoted SRC
further in a dose-dependent manner at 8 hr after activation (Fig-
ures S1J–S1L).
CD28 Costimulation Transiently Limits Mitochondrial
Sphericity Early after T Cell Activation and during
Metabolic Stress
We have previously shown that mitochondrial morphology influ-
ences T cell metabolism (Buck et al., 2016). We therefore
analyzed mitochondrial shape in T cells at different times after
activation ± aCD28. T cells primed (+) aCD28 displayed elon-
gated mitochondria early after activation (Buck et al., 2016;
Ron-Harel et al., 2016), whereas T cells primed () aCD28 had
more spherical mitochondria (Figures 2A, S2A, and S2B). Spher-
ical mitochondria are associated with rapidly dividing glycolytic
T cells (Buck et al., 2016), a phenotype observed in mature
IL-2 TE cells primed ± aCD28 (Figures 2A andS2B). IL-15 TM cells
primed (+) aCD28 contained tubulated mitochondria, while cells
primed () aCD28 appeared less tubulated (Figure 2A). Unlike
IL-2 TE cells primed (+) CD28, mitochondria in cells initiallyial Respiratory Capacity
-2 (100 U/mL), and ± soluble aCD28 (0.5 mg/mL).
re measured for 8 hr after activation with aCD3 beads ± aCD28 in a Seahorse
pacity (SRC), after oligomycin (Oligo) and FCCP respectively, were quantified.
ells and SRCwas assessed (calculated as (OCR after FCCP – basal OCR)/basal
15-week-old uninfected age and sex-matchedWT and CD80/86/mice. OCR
ycin (R+A). Graphs represented as mean ± SEM of three biological replicates.
d IL-2. OCR was followed for 8 hr and maximal respiration was assessed by
cytometry (% IFN-g+ CD8+ T cells and MFI of IFN-g is shown).
e glucose restriction) overnight (lower panels). Baseline ECAR was determined
ical comparisons for two groups were calculated by using unpaired two-tailed
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primed () aCD28 appeared less elongated in response to AGR
(Figure 2B), correlating with their lack of SRC (Figure 1H). There-
fore, CD28 signals during activation affect mitochondrial
morphology in T cells.
Mitochondrial Cristae Loosening in T Cells Is
Accelerated in the Absence of CD28 Costimulation
Nutrient availability modulates mitochondrial remodeling (Ram-
bold et al., 2015; Senyilmaz et al., 2015). It has been shown
that tight cristae support efficient OXPHOS (Cogliati et al.,
2013) and loose cristae facilitate aerobic glycolysis in T cells
(Buck et al., 2016). We found that T cells primed () aCD28
had significantly looser cristae 8 hr after activation, a phenotype
propagated through IL-15 TM cell development (Figures 2C, 2D,
and S2C) and also evident in TE cells under AGR (Figures 2C and
2D), consistent with their inability to invoke efficient OXPHOS
when required (Figures 1G and 1H). These data suggested that
CD28 costimulation restrained cristae loosening after TCR acti-
vation, and this early CD28 signal conferred the ability to main-
tain, or revert, to this morphological state throughout the life of
the cells (Figure 2D). TN cells, and in vitro and in vivo generated
TM cells, had tighter cristae than their TE cell counterparts (Fig-
ure 2E). Together, these data suggest cristae loosening is accel-
erated in T cells activated () CD28 and that they are never able
to properly retighten their cristae after initial priming, a process
that is important for TM cells. This early morphological change
correlates with their persistent lack of SRC.
CD28-Mediated SRC and IL-15 TM Cell Cytokine
Production Is Inhibited by ETO or Cpt1a Knockdown
FAO and SRC are evident in long-lived TM cells (Pearce et al.,
2009; van der Windt et al., 2012). To determine whether CD28 in-
fluences FAO early after activation, we measured SRC in T cells
primed ± aCD28 in the presence of (+) etomoxir (ETO), an irre-
versible inhibitor of Cpt1a, the rate-limiting enzyme for mito-
chondrial b-oxidation of long-chain fatty acids (Lopaschuk
et al., 1988). ETO abrogated CD28-induced SRC (Figure 3A),
suggesting that CD28 promoted Cpt1a function early after acti-
vation to support SRC, a result we confirmed genetically by intro-
ducing Cpt1a siRNA into TN cells to knock down this protein prior
to activation (Figures S3A and S3B). To assess whether CD28-
mediated FAO was influenced by altered fatty acid uptake, we
cultured T cells primed ± CD28 with bodipy-labeled palmitate
and found no difference in acquisition 8 or 24 hr later (Fig-
ure S3C). IL-15 TM cells that were originally derived from a TE
cell population primed (+) ETO, but subsequently cultured
without ETO, showed impaired SRC, and injection of ETO onto
control IL-15 TM cells reduced maximal OCR after FCCP to theFigure 2. CD28 Costimulation Regulates Mitochondrial Sphericity and
(A) Mitochondrial morphology in PhAM CD8+ T cells over time after aCD3 ± aCD2
nuclei are blue (Hoechst). Scale bar, 5 mm. Histograms depict sphericity of the m
(B) Confocal images of PhAM CD8+ TE cells cultured in 0.3 mM Glc overnight.
(C) Electron microscopy (EM) analysis of cells cultured as in (A) and (B). Scale ba
(D) Cristae width over time after activation. Bar graph depictsmean ±SEMofmaxi
using Fiji/ImageJ software. Statistical comparisons for two groups were calculat
(E) Cristae width assessed as in (D) from in vitro cultured and ex vivo isolated TN
See also Figure S2.level observed in cells activated () aCD28or (+) ETO (Figure 3B).
We also found that the decreased SRC in ex vivo TM cells iso-
lated from CD80/86/ mice was less sensitive to ETO when
compared to wild-type (WT) TM cells, suggesting their reduced
FAO (Figure S3D). Cells primed (+) aCD28 and (+) ETO did not
robustly produce interferon (IFN)-g upon restimulation (Fig-
ure 3C), similar to that observed in IL-15 TM cells initially primed
() aCD28 (Figure 1F). We confirmed this result genetically by
transducing TN cells prior to activation with Cpt1a-shRNA (sh)
and then differentiating them toward the TM phenotype. Upon re-
stimulation, the cells that expressed Cpt1a-sh during priming
produced less IFN-g later (Figures S3E and S3F), consistent
with their inability to form robust TM cells.
CD28-Mediated Mitochondrial Remodeling Is Inhibited
by Etomoxir
ETO treatment during the first 48 hr after activation also affected
CD28-mediated mitochondrial remodeling in cells 8 hr later, in
IL-2 TE cells after AGR, and in cells cultured toward the TM
phenotype as mitochondria looked more punctate in these
groups compared to controls (Figure 3D). Cristae in T cells
treated (+) ETO during priming were similar to those activated
() aCD28, such that 8 hr after activation, AGR, and IL-15 TM
cell differentiation, cristae were significantly wider than in control
cells (Figures 3E, 3F, and S3G). These data suggest that CD28
signals engage FAO early after initial priming, and cristae are re-
modeled during this process.
Given that Opa1 is important for TM cell formation (Buck et al.,
2016), we assessed whether enhanced Opa1 expression could
compensate for the loss of CD28 costimulation. We primed
T cells from OPA1-transgenic (OPA1TG) mice, which express
1.5- to 2.0-fold more OPA1 than WT cells (Cogliati et al.,
2013), ± CD28 and then measured cristae width 8 hr later. While
the OPA1TG cells had tighter cristae than those in WT cells when
activated (+) CD28, activation () CD28 still led to reduced
cristae tightness, independent of the presence of more OPA1
(Figure S3H). These observations suggest that although OPA1
overexpression enhances cristae tightness in T cells after activa-
tion, this alone is not sufficient to compensate for signals medi-
ated by CD28.
To further assess metabolism in T cells primed ± CD28 we
cultured cells with 13C-glucose, 13C-glutamine, and 13C-palmi-
tate and traced carbons from these substrates into metabolites
(Figure S4). We found that carbons from glucose and gluta-
mine were equally incorporated into the metabolites mea-
sured between cells primed ± CD28 or ± ETO, with the
exception that there was slightly increased glucose-derived
carbon in palmitate in cells primed (+) aCD28 (Figures S4ACristae Morphology in T Cells
8 activation and differential cytokine culture. Mitochondria are green (GFP) and
itochondria as determined by Imaris software (see Figures S2A and S2B).
r, 200 nm.
mum cristae width in arbitrary units, measured from 15 images from each group
ed by using unpaired two-tailed Student’s t test, ***p < 0.0001; *p < 0.05.
, TE, and TM cells.






Figure 3. CD28-Mediated SRC and Mitochondrial Remodeling during Metabolic Stress Is Dependent on Cpt1a Function
Naive CD8+ T cells were activated with bead- or plate-bound aCD3, IL-2, soluble aCD28, and ±200 mM etomoxir (ETO).
(A) OCR was measured for 8 hr after activation with aCD3 beads ± aCD28, ± 200 mM ETO. SRC after FCCP was quantified. ***p < 0.001.
(B) Cells were primed for 48 hr as in (A), 3 days after activation cells were switched to IL-15 for 3 days to generate IL-15 TM cells and SRC was assessed.
(C) IL- 15 TM cells were restimulated and intracellular IFN-gwas assessed by flow cytometry. IFN-g
+ CD8+ T cells and MFI of IFN-g is shown (control is the same
plot in Figure 1F).
(D) Confocal images of PhAM CD8+ T cells, activated with aCD3/28 ± 200 mM etomoxir, 8 hr after activation, TE cultured in AGR conditions overnight, and
differentiated toward the TM phenotype. Scale bar, 2 mm.
(E) EM analysis of cells cultured as in (A) and (B). Scale bar, 200 nm.
(F) Cristae width over time after activation, aCD3/28 control measurements from Figure 2D. Bar graph depicts mean ± SEM of maximum cristae width in arbitrary
units, measured from 15 images from each group using Fiji/ImageJ software. * p < 0.05; **p < 0.01; ***p < 0.001.
(A and B) Data shown as mean ± SEM, representative ofR 3 separate experiments.
See also Figures S3 and S4.
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Figure 4. T Cells Primed without CD28 Costimulation, or in the Presence of ETO, Fail to Provide Protective Immunity against Tumor
Challenge In Vivo
C57BL/6 mice were inoculated subcutaneously (s.c.) with 106 EL4-OVA cells. After 5 days, 5 3 106 congenically marked OT-I TE cells initially primed with
aCD3 ± aCD28 ± ETO (left) were transferred intravenously (i.v.) into recipients and tumor growth was assessed (middle). Circulating Kb/OVA-specific donor cells
(Tet+) assessed by flow cytometry (right). Shown as mean ± SEM (n = 5–6/group). Statistical comparisons were calculated by using one-way ANOVA with
Bonferroni’s multiple comparison tests, ***p < 0.0001; **p < 0.01; *p < 0.05.
See also Figures S3 and S4.and S4B). The only significant difference we observed was
enhanced incorporation of palmitate carbon into fumarate,
indicating greater incorporation of palmitate into TCA cycle in-
termediates, which was generally supported by elevated incor-
poration into glutamate and malate, in cells primed (+) CD28
(Figures S4C and S4D). Cells primed (+) ETO showed a reduc-
tion of palmitate-derived carbon, but not of glucose- or gluta-
mine-derived carbon, in TCA cycle intermediates, similar to
cells () CD28. These data indicate that in this context ETO in-
hibits mitochondrial FAO in T cells, while not affecting utilization
of other OXPHOS substrates. Overall, these findings are
consistent with altered fatty acid metabolism as a result of
CD28 costimulation in these cells.
T Cells Primed without CD28 Costimulation, or in the
Presence of ETO, Fail to Provide Protective Immunity
against Tumor Challenge In Vivo
Lack of CD28 costimulation during activation generates anergic
TM cells that cannot respond to further antigen challenge in vivo
(Borowski et al., 2007; Esensten et al., 2016; Mittru¨cker et al.,
2001; Villegas et al., 1999). We investigated whether CD28-
mediated mitochondrial changes that facilitate FAO were also
important for efficient recall responses in vivo. Ovalbumin
(OVA)-specific OT-I+ T cells were activated with aCD3 ±
aCD28 and ± ETO for 48 hr, expanded for a further 24 hr in me-
dium containing only IL-2, and then adoptively transferred into
mice bearing OVA-expressing EL4 (EL4-OVA) tumors (Figure 4).
5/5 mice that received no OT-I+ T cells did not control tumor
growth and were sacrificed 15 days after tumor implantation,
while 6/6 mice that received aCD3/28-activated OT-I+ T cells
cleared tumors within 12 days (Figure 4). 4/5 mice that received
OT-I+ T cells that were primed () aCD28 (i.e., aCD3 only), and
5/5 mice that received OT-I+ T cells activated with aCD3/CD28
(+) ETO initially controlled tumor burden, indicating the develop-
ment of a primary TE response. However, these cells were unable
to control tumor regrowth weeks later, suggesting a lack of pro-
tective TM cells with the capacity to eradicate the cancer andprovide long-lasting immunity (Figure 4). OT-I+ donor T cells in
mice persisted in similar frequencies in all 3 groups in the weeks
following adoptive transfer (Figure 4), indicating that the inability
to control tumors was not due to a lack of survival of the cells
primed () aCD28 or (+) ETO, but rather stemmed from a defect
in their functional capacity. Together, these data suggest that
CD28 provides an early signal to enhance Cpt1a function and
build SRC in the mitochondria at the time of TCR activation,
and this regulates the ability of the ensuing TM population to
function appropriately and provide protective immunity against
tumor challenge.
MicroRNA-33, a Target of Thioredoxin-Interacting
Protein, Attenuates Cpt1a Expression in the Absence
of CD28
To investigate how CD28 might modulate Cpt1a function, we
analyzed published mRNA expression data of CD4+ T cells stim-
ulated with aCD3 ± CD28 (Martı´nez-Llordella et al., 2013). In the
top 100 differentially regulated genes, many were related to
mitochondrial metabolism, including thioredoxin-interacting
protein (TXNIP), which was in the top 10 genes regulated
by CD28 (Figure S5A). Previous studies have described a role
for TXNIP in mitochondrial metabolism (Chen et al., 2016;
DeBalsi et al., 2014; Zhou et al., 2010) and in the regulation of
microRNA-33 (miR33), a microRNA linked to the suppression
of FAO (Ouimet et al., 2015; Rayner et al., 2011; Zhou et al.,
2010). Cpt1a is a known target of miR33 (Da´valos et al., 2011),
which hinted at a possible regulatory axis of CD28-TXNIP-
miR33-Cpt1a.
We found that TXNIP protein was modestly decreased in
T cells primed (+) aCD28, which coincided with increased
Cpt1a protein 24 hr after activation (Figures 5A–5C). This differ-
ence was no longer evident 48 hr after activation (Figure S5B),
suggesting that the transient induction of Cpt1a protein, and
associated increase in SRC (Figure 1A), occurs only during the
priming phase. TXNIP protein was also slightly decreased in
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increased CPT1A protein 24 hr after activation (Figures 5D, 5E,
and S5C–S5E).
To further investigate the relationship between CD28 and
CPT1A in human T cells, we generated 1st and 2nd generation hu-
man chimeric antigen receptor (CAR) T cells targeting the brain
tumor antigen AC133/CD133. We observed increased CPT1A
expression in the 2nd generation CAR T cells that contained
CD3z along with the CD28 intracellular signaling domain when
compared to the 1st generation CAR T cells that only contained
the CD3z domain, 24 hr after activation (Figure 5F). We also de-
tected an increase in CPT1A in the 1st generation CAR T cells
supplemented with soluble CD28 (Figure S5F).
We observed that miR33 expression in T cells primed (+)
aCD28 was reduced after 24 hr compared to cells primed ()
aCD28 (Figure 5G) and inversely correlated with the expression
of Cpt1a protein at this time (Figures 5A–5C), suggesting a
possible causality between miR33 suppression and Cpt1a in-
duction. We reasoned that manipulating miR33 expression in
T cells during the first 48 hr after activation () aCD28 should
recapitulate the effects of activation (+) aCD28 on Cpta1 expres-
sion. Introducing anti-miR33 into T cells primed () aCD28 pro-
moted Cpt1a expression to the level observed in (+) aCD28
T cells with the control miR (Figure 5H), while a miR33 mimetic
suppressed Cpt1a expression in cells primed ± aCD28 when
compared to cells with the control miR (Figure 5H). Additionally,
anti-miR expression in cells primed (+) aCD28 led to an evenFigure 5. The Thioredoxin-Interacting Protein Target MicroRNA-33 Att
(A) Western blot analysis at 24 hr after activation with aCD3 ± aCD28. Signals sho
protein (TXNIP) ratio at 24 hr after activation, n = 4 biological replicates. Densitom
step card of Kodak MR film, y = 0.021046xe0.014751x and R = 0.98635).
(B) TN cells were activated using aCD3 ± aCD28 and Cpt1a protein levels were m
biological replicates. ***p < 0.001.
(C) Naive T cells activated as in (B) were assessed for TXNIP and Cpt1a expre
activation from 3 biological replicates. *p < 0.05.
(D) Human CD8+ TN cells were enriched using magnetic bead negative selectio
extracts were assessed for TXNIP protein levels. Bar graphs represent relative TXN
using densitometry from blots shown in Figure S5C. Bar graphs represent mean
(E) Flow cytometric analysis of human CD8+ TN cells activated as in (D) for CPT1A
of >3 experiments. A repeat experiment showing the same trends is shown in Fi
(F) Human CD8+ TN cells were electroporated with an AC133/CD133-specific firs
were rested overnight and then exposed to the murine EL4 lymphoma cell line ex
ratio of 5:1 tumor to T cell to ensure maximal activation. 24 hr after activation,
cytometry. Bar graphs depict mean ± SEM of the ratio of CPT1A expression b
Calculations depicted are of three independent experiments. ***p < 0.001.
(G) miR33 expression by qRT-PCR at 24 and 48 hr after activation with aCD3 ±
(H) 3 pmol of oligonucleotides were electroporated into TN cells using the Amaxa n
after activation Cpt1a protein levels were measured by flow cytometry. Histogra
(I) aCD3/28 cells generated with anti-microRNA-33 (miR33) or miR33-mimetic g
Intracellular IFN-g was assessed by flow cytometry (% IFN-g+ CD8+ T cells and
(J) EM of control or miR33-mimetic cells generated as in (I).
(K) Bar graph depicts mean ± SEM ofmaximum cristae width in arbitrary units, me
comparisons for two groups were calculated by using unpaired two-tailed Stude
(L) Proposed model shows regulation of Cpt1a function and FAO by CD28. CD2
mitochondrial FAO, before the first cell division, coinciding with mitochondrial elon
a target of thioredoxin-interacting protein (TXNIP), attenuates Cpt1a expression in
T cells after activation. Cpt1a-mediated FAO can be blocked by miR33 expression
is associated with reduced premature mitochondrial sphericity and excessive cri
capacity to ‘‘recoil,’’ a process crucial for the generation of the long-lasting metab
cells. This early transient CD28-dependent FAO prevents premature mitochond
metabolic reserve.
See also Figure S5.further increase in Cpt1a (Figure 5H), suggesting that Cpt1a
may not be expressedmaximally after priming (+) aCD28, raising
the possibility that additional costimulatory signals could in-
crease its expression further in other settings (Kawalekar
et al., 2016).
miR33 Expression during Naive T Cell Priming
Modulates Cytokine Production andCristaeMorphology
in IL-15 TM Cells
To test the effects of transient miR33 expression during T cell
priming on T cell function after TM cell differentiation, we intro-
duced anti-miR33 and miR33 mimetic into TN cells that were
subsequently primed (+) aCD28 and differentiated to IL-15 TM
cells. Anti-miR33 increased IFN-g production upon restimulation
in comparison to T cells with control miR, while the miR33
mimetic dampened IFN-g production, confirming that the regu-
lation of miR33 during T cell activation influences the long-lasting
functional capacity of future TM cells (Figure 5I). Much like inhib-
iting Cpta1with ETO, introduction of themiR33mimetic results in
looser cristae in T cells cultured toward the TM phenotype (Fig-
ures 5J and 5K).
DISCUSSION
We show here that CD28 ligation during priming endows T cells
with mitochondrial capacity that is important for future T cellenuates Cpt1a Expression in the Absence of CD28 Costimulation
wn from a single western blot; bar graph depicts Cpt1a/thioredoxin-interacting
etry measurements made in ImageJ and converted to optical density (density
easured by flow cytometry. Bar graphs represented as mean ± SEM from three
ssion by flow cytometry. Bar graph depicts Cpt1a/TXNIP ratio at 24 hr after
n (Stem Cell Technologies). 24 hr after activation with aCD3 ± aCD28 protein
IP expression between ± aCD28 activation conditions. Ratios were calculated
± SEM of three healthy donors. *p < 0.05.
protein expression. Bar graphs represent mean ± SEM, and are representative
gure S5D.
t or second-generation chimeric antigen receptor (CAR). Electroporated cells
pressing the exogenous CAR target AC133/CD133 in the presence of IL-2 at a
CPT1A expression was analyzed in the CAR+ cells (Myc tag staining) by flow
etween first and second generation CAR T cells from the same experiment.
aCD28 (n = 4 samples). **p < 0.01.
ucleofector, cells were rested for 4 hr and activated using aCD3 ± aCD28. 24 hr
ms representative of 3 biological replicates.
enerated as in (D) were differentiated toward IL-15 TM cells and restimulated.
MFI of IFN-g is shown).
asured from >25 images from each group using Fiji/ImageJ software. Statistical
nt’s t test, ***p < 0.0001.
8 signals transiently promote expression of Cpt1a, a rate-limiting enzyme for
gation and enhanced spare respiratory capacity (SRC). microRNA-33 (miR33),
the absence of CD28. Cpt1a expression influences FAO engagement in CD8+
or ETO treatment. This early transient CD28-dependent Cpt1a-mediated FAO
stae loosening (depicted as a spring), which endows the mitochondria with the
olic reserve that is essential for the appropriate functional recall capacity of TM
rial sphericity and is crucial for the generation of long-lasting mitochondrial
Cell 171, 385–397, October 5, 2017 393
responses. We speculate that CD28 temporarily restricts TXNIP
and miR33 expression, and this leads to a transient induction of
Cpt1a and FAO, which are marked by characteristic changes in
mitochondria shape and structure. Early CD28 signals restrain
cristae loosening immediately after T cell activation, and we sur-
mise that this process grants mitochondria a rebound capacity
that is critical for future SRC and function. The changes in mito-
chondrial morphology and inner cristae structure we observed
in T cells after activation can determine metabolic pathway
engagement (Buck et al., 2016). Much like an overstretched
spring, initial T cell priming without costimulation results in slack
cristae without a future ability to robustly recoil (Figure 5L). Pre-
cisely how CD28 signals restrain mitochondrial sphericity after
T cell activation and how this process imparts durable changes
to the mitochondria that are remembered by future daughter
cells remains a subject of investigation. Our data show that acti-
vated OPA1TG T cells tighten cristae even further in response to
CD28 costimulation, suggesting that CD28 signals mediate fac-
tors beyond OPA1. CD28 signals can enhance cell survival
through induction of the mitochondrial modulator Bcl-XL (Boise
et al., 1995). Whether this CD28-mediated signal, or whether
additional functions of Cpt1a beyond FAO, influence the mito-
chondrial fission and fusion machinery that are critical regulators
of TM cells (Buck et al., 2016), or contribute to mitochondrial
morphology and metabolism, is of future interest.
Conceptually, the ability to engineer cells to adopt a particular
metabolism that favors optimal immune cell performance in
different disease settings is a basis for therapeutically targeting
immunometabolism (O’Sullivan and Pearce, 2015). Much like
cancer cells that rewire metabolism toward the Warburg effect,
other cell types like T cells can also be forced to rewire meta-
bolism. Genetic changes can lead to metabolic changes that
allow cells to persist in the face of differing environmental
stresses or conditions. In this context, a recent report has shown
that persistently elevated glycolytic metabolism due to von
Hippel-Lindau (Vhl)-deficiency, which enforces constitutive hyp-
oxia-inducible factor (HIF) activation, can support the develop-
ment of a persistent effector memory T (TEM) cell population
(Phan et al., 2016). These data suggest that reprogramming a
cell to engage aerobic glycolysis with enhanced HIF activity
alters its need to rely on mitochondrial processes such as
OXPHOS during TM cell development by providing another
means by which to obtain energy. However, it is important to
stress that under physiological conditions, the engagement of
OXPHOS and associated loss of clonal expansion, with acquisi-
tion of homeostatic self-renewal coupled to cellular persistence,
is a critical component of the normal T cell response. Therefore,
while OXPHOS and SRC are not requirements for the develop-
ment of persistent Vhl-deficient TEM cells (Phan et al., 2016),
the data do not exclude that these parameters are important
for normal TM cell development and function, and in particular,
for the development of central memory (TCM) cells. Studies
continue to support a role for both OXPHOS and SRC in TM cells
(Fraser et al., 2013; Kawalekar et al., 2016; Sukumar et al., 2013,
2016), andwe show here that these attributes are also influenced
by CD28 during initial activation.
Our data support that there is more FAO in T cells with tight
mitochondrial cristae as a result of CD28 signaling, when394 Cell 171, 385–397, October 5, 2017compared to () CD28 cells. After tracing carbons derived
from palmitate, glucose, and glutamine, the only significant dif-
ference observed between cells ± CD28 was the increased
incorporation of palmitate into TCA intermediates, an increase
lost with ETO treatment. These changes in metabolism were
accompanied by the loosening of cristae and by blunted SRC,
an effect also observed following Cpt1a knockdown. Impor-
tantly, the metabolomics data showed that mitochondria with
either loose or tight cristae oxidized glucose and glutamine,
and the fractional contribution to TCA intermediates remained
equal. In contrast, (+) CD28 cells with tight cristae exhibited
increased oxidation of labeled palmitate. Thus, it is not that the
cells containing mitochondria with tight cristae switch to a pref-
erential usage of FA as a result of CD28, but rather, they burn
significantly more FA than () CD28 cells with loose cristae.
These observations suggest that in this context, the enhanced
FAO is not at the expense of glucose or glutamine utilization,
but rather our data support the notion that engagement of FAO
confers a metabolic advantage to cells that received CD28 cos-
timulation. It is worth noting only 5% label is found in cellular
palmitate after 24 hr, perhaps suggesting that FAO of exogenous
palmitate is inefficient. This assay does not measure oxidation of
unlabeled endogenous FA stores, which could also significantly
contribute to FAO in these cells.
It may not be that mitochondria with tight cristae always use
more FAO than those with loose cristae. Opa1-deficient T cells
have loose cristae and maintain OXPHOS that is ETO-sensitive,
indicating that these cells can engage FAO (Buck et al., 2016).
However, Opa1/ T cells lack SRC and do not efficiently form
TM cells. Thus, tight cristae are not an absolute requirement for
FAO, but appear to be required for SRC. We believe that these
data suggest that FAO via Cpt1a function, and tight cristae
with SRC, are linked processes in that they are both important
for the development of functional TM cells. Further studies might
uncover how these pathways are related.
While off-target effects can be a concern when using inhibi-
tors, our approach of using ETO allowed us to transiently inhibit
Cpt1a function during T cell priming, when initial costimulatory
signals from CD28 are present. To address the concern that
ETO may have effects beyond inhibiting Cpt1a and FAO, we
introduced a Cpt1a-small hairpin RNA (shRNA) (sh), or a Cpt1a
small interfering RNA (siRNA), into TN cells to knock down this
protein prior to activation. By genetically targeting Cpt1a we
could illustrate that the SRC observed early after activation
was Cpt1a-dependent, and correlate this with the fact that the
future function of the TM cells derived from these TN cells was
compromised. These results phenocopied those observed with
ETO treatment during activation, supporting that in this context
ETO inhibits Cpt1a function.
Interestingly, we observed spherical mitochondria 8 hr after
activation in the absence of CD28 costimulation, or in the pres-
ence of ETO, which was at a time before significant differences
in Cpt1a protein expression were measureable. This could be
because only a very subtle increase in Cpt1a is needed for its
effect on mitochondrial metabolism, as Cpt1a enzyme activity
has been linked to expression levels (Akkaoui et al., 2009). While
Cpt1a protein is significantly increased at 24 hr after activation
with CD28 costimulation, changes in the regulation of Cpt1a
activity could also happen earlier, for example, through differ-
ences in its mitochondrial membrane localization, interactions
within the mitochondrial fatty acid transport complex (Lee
et al., 2011), or its steric regulation via changing malonyl CoA
concentrations (McGarry et al., 1977). This type of change in
regulation could contribute to Cpt1a function and associated ef-
fects on mitochondrial morphology. When taken together, the
data suggest that mitochondrial dynamics can be modulated
downstream of CD28, which itself regulates Cpt1a activity
and FAO.
While TXNIP-miR33-Cpt1a regulation of FAO is well estab-
lished in the literature (Chen et al., 2016; Da´valos et al., 2011;
Goedeke et al., 2013), this does not preclude the involvement
of other targets in the regulation of CD28-mediated mitochon-
drial remodeling. However, the inhibition of TM cell recall ability
evident in T cells activated () CD28, or T cells activated (+)
CD28 with enhanced miR33 expression or reduced Cpt1a func-
tion, suggests that the miR33-Cpt1a axis is, at least in part, a
mechanism that mediates the function of CD28 regulated mito-
chondrial remodeling and fatty acid metabolism. It will be of
interest for future studies to profile all miR33 targets in these
cells to potentially identify druggable proteins in this pathway
beyond Cpt1a that modulate mitochondrial function during
T cell activation.
As costimulatory molecules are immunotherapeutic targets
and incorporation of their signaling domains can affect the func-
tional capacity of CAR T cells (Esensten et al., 2016; Fesnak
et al., 2016; Kawalekar et al., 2016), research into this area is
highly relevant. Interestingly, recent evidence shows that PD-1
modulates FAO in T cells (Da´valos et al., 2011), suggesting that
other pathways that influence T cell activation can also regulate
mitochondrial processes. It has been shown that the inclusion of
a 4-1BB intracellular domain in the CAR leads to T cells with a
more oxidative metabolism when compared to CD28 containing
CAR T cells (Kawalekar et al., 2016). A constant signal through
CD28, long after activation, leads to CAR T cells with an ex-
hausted phenotype (Long et al., 2015). It is possible that only a
transient costimulatory signal from CD28, combined with the
4-1BB intracellular domain in the CAR, would lead to an opti-
mally activated CAR T cell that is resistant to exhaustion in vivo.
Understanding precisely how inhibitory receptors and costimu-
latory molecules regulate immune cell metabolism and mito-
chondrial processes is critical for effectively harnessing these
molecules for therapy. While it has been known for more than
30 years that CD28 is important for promoting T cell activation
(Martin et al., 1986; Weiss et al., 1986) and glycolysis (Frauwirth
et al., 2002; Jacobs et al., 2008; MacIver et al., 2013), we now
expand our knowledge to show that signals from this receptor
also endow mitochondria with latent metabolic capacity that is
essential for future T cell responses.STAR+METHODS
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Rabbit polyclonal Anti-Cpt1a Proteintech Group Cat#15184-1-AP RRID: AB_2084676
Rabbit polyclonal anti-TXNIP Cell Signaling technologies Cat#14715
Rabbit monoclonal anti-GAPDH Cell Signaling technologies Cat#5174P
anti-mouse CD3 BioLegend BioLegend Cat# 100223 RRID: AB_1877072
anti-human CD3 BioLegend Cat# 300314 RRID: AB_314050
anti-mouse CD28 BioLegend BioLegend Cat# 102112 RRID: AB_312877
anti-human CD28 BioLegend Cat# 302923 RRID: AB_2291210
Bacterial and Virus Strains
Luciferase shRNA (pLMP-GFP backbone) van der Windt et al., 2012 N/A
Cpt1a shRNA (pLMP-GFP backbone) van der Windt et al., 2012 N/A
Biological Samples
Healthy control blood UniKlinik Freiburg N/A
Chemicals, Peptides, and Recombinant Proteins
SIINFEKL peptide (high-affinity OVA peptide) New England Peptide http://www.newenglandpeptide.com/services/
peptides/custom-peptide-synthesis
SIIQFEKL peptide (low-affinity OVA peptide) New England Peptide http://www.newenglandpeptide.com/services/
peptides/custom-peptide-synthesis
human CTLA4-Ig fusion protein BioXcell Cat# BE0099
human fc-Ig fusion protein BioXcell Cat# BE0096
Recombinant human IL-2 Peprotech Cat# 200-02
Recombinant murine IL-15 Peprotech Cat# 210-15
Recombinant human IL-15 Peprotech Cat# 200-15
Oligomycin Sigma CAS# 1404-19-9
FCCP Sigma CAS# 370-86-5
Etomoxir Tocris Biosciences CAS# 828934-41-4
Rotenone Sigma CAS# 83-79-4
Antimycin A Sigma CAS# 1397-94-0
Critical Commercial Assays
Seahorse extracellular flux analyzer XFe 96 Agilent http://www.agilent.com/cs/ContentServer?
c=Page&pagename=Sapphire/Page/HomePage
Nucleofector electroporator (+ primary cell solution 3) Lonza http://www.lonza.com
TaqMan MicroRNA Cells-to-CT Kit Life Technologies Cat# 4391848
Accell siRNA Delivery Media GE Dharmacon Cat# B-005000
Experimental Models: Cell Lines
EL4-OVA ATCC ATCC Cat# CRL-2113, RRID: CVCL_3505
Experimental Models: Organisms/Strains
C57BL/6J mice Jackson laboratories RRID: IMSR_JAX:000664
CD80/86/ mice Jackson laboratories RRID: IMSR_JAX:003610
PhAM mice Jackson laboratories RRID: IMSR_JAX:018397
OT-I mice Jackson laboratories RRID: IMSR_JAX:003831
CD45.1 congenic mice Jackson laboratories RRID: IMSR_JAX:002014
Oligonucleotides
siRNA for murine Cpt1a GE Dharmacon Cat# E-042456-00-0005
AntiMir33-5p Life Technologies Cat# AM12410
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Mir33-5p Life Technologies Cat# MC12410
mmu-miR-33-5p (Assay ID: 002135) Life Technologies Cat# 4427975
Hprt (Mm03024075_m1) Life Technologies Cat# 4331182
Recombinant DNA
Plasmid: pMAX-GFP (control vector in nucleofector kit) Lonza N/A
Software and Algorithms
Wave software version 2.4 Agilent http://www.agilent.com/cs/ContentServer?
c=Page&pagename=Sapphire/Page/HomePage
FlowJO FlowJO https://www.flowjo.com
Graphpad Prism 6 (seahorse and statistical analysis) Graphpad software http://www.graphpad.comCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be made available upon reasonable
request by the Lead Contact, Erika L. Pearce (pearce@ie-freiburg.mpg.de).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mouse Models
C57BL/6J (RRID: IMSR_JAX:000664), CD80/86/ (RRID: IMSR_JAX:003610), PhAM (RRID: IMSR_JAX:018397) (Pham et al., 2012),
major histocompatibility complex (MHC) class I-restricted OVA specific TCR OT-I transgenic mice (RRID: IMSR_JAX:003831), and
CD45.1 congenic (RRID: IMSR_JAX:002014) mouse strains were purchased from The Jackson Laboratory and were maintained
at the Max Planck institute for Immunobiology and cared for according to the Institutional Animal Use and Care Guidelines. Tumor
studieswere approved by the animal care committee of the Regierungspraesidium Freiburg.Micewere bred under specific pathogen
free standards, and transferred to open top cages for experimental procedures. For tumor experiments 8-15 week old mice were
randomized to match age and gender across experimental groups. Temperature and humidity of the holding rooms was monitored
daily and tumor bearing mice were weighed every 2 days. No association of sex or weight with response was observed or expected.
Primary cell cultures
Naive CD8+ T cells were obtained from total splenocytes isolated from 6-9 week old C57/B6mice using the naive CD8 T cell kit (Stem
Cell technologies) according to themanufacturers protocol. Within experiments micewere age and sexmatched. Sample size is indi-
cated in the figure legends. Fresh buffy coats from healthy donors were collected from the Blood Donation Center of the University
Hospital Freiburg, under approval by the ethical committee of the University of Freiburg. Naive human CD8 T cells were isolated by a
naive CD8 T cell kit (Stem Cell technologies, Cat# 19258). Researchers were blinded to the identity of the donors, and age or sex
matching was not performed. Sample size is indicated in the figure legends. Isolated T cells were activated using plate bound
aCD3 (5 mg/ml) (anti-mouse CD3, BioLegend Cat# 100223 RRID: AB_1877072 ; anti-human CD3 BioLegend Cat# 300314 RRID:
AB_314050), in 1640 media supplemented with 10% fetal calf serum, 4mM L-glutamine, 1% penicillin/streptomycin, 100 U/ml
hrIL-2 (Peprotech), 55mMbeta-mercaptoethanol, and ± 0.5 mg/ml soluble aCD28 and ± 200 mMEtomoxir under 5%CO2, atmospheric
oxygen, at 37C in a humidified incubator.
Cell lines
The murine EL4 lymphoblast cell line expressing OVA (EL4-OVA; E.G7-OVA), was purchased from ATCC (ATCC Cat# CRL-2113,
RRID: CVCL_3505), cultured for three passages before being implanted in the flank of naive mice. Further authentication of this
cell line was not performed. The sex of the cell line is female. Cells were maintained in 1640 media supplemented with 10% fetal
calf serum, 4mM L-glutamine, 1% penicillin/streptomycin, 55 mM beta-mercaptoethanol, under 5% CO2, atmospheric oxygen, at
37C in a humidified incubator.
METHOD DETAILS
In vivo tumor experiments
C57BL/6 mice were injected subcutaneously into the right flank of mice with 1 x106 EL4-OVA. After 5 days, 5 3 106 congenically
marked OT-I TE, that had previously been activated in vitro with aCD3, aCD3/CD28 or aCD3/CD28 +ETO, were transferred i.v.
into mice randomized from littermate cages and tumor growth was assessed. Tumor measurements were not acquired blinded,Cell 171, 385–397.e1–e4, October 5, 2017 e2
but reproducibly acquired by multiple investigators. A small quantity of blood was obtained at indicated time points to quantify OVA-
specific CD8+ T cells by flow cytometry.
Primary T cell isolation and culture
Naive CD8+ T cells were obtained from total splenocytes isolated from 6-9 week old C57/B6mice using the naive CD8 T cell kit (Stem
Cell technologies, Cat# 19858) according to the manufacturers protocol. Naive human CD8 T cells were isolated using a negative
selection kit (Stem Cell technologies, Cat# 19258). Isolated T cells were activated using plate bound aCD3 (5 mg/ml) (anti-mouse
CD3, BioLegend Cat# 100223 RRID: AB_1877072 ; anti-human CD3 BioLegend Cat# 300314 RRID: AB_314050), in 1640 media
supplemented with 10% fetal calf serum, 4mM L-glutamine, 1% penicillin/streptomycin, 100 U/ml hrIL-2 (Peprotech), 55mM beta-
mercaptoethanol, and ± 0.5 mg/ml soluble aCD28 (anti-mouse CD28 BioLegend Cat# 102112 RRID: AB_312877; anti-human
CD28 BioLegend Cat# 302923 RRID: AB_2291210) and ± 200 mM Etomoxir. Media changes were performed at D2 (removing
Etomoxir). For TM cell cultures, T cells at D3 after activation were plated in media containing 100U/ml IL-15 (Peprotech) followed
by media changes on D4 and D5. TM cells were analyzed or reactivated day 6 after initial activation. For acute glucose restriction
(AGR), cells were plated in complete media supplemented with dialyzed serum and the indicated glucose amounts for 24 hr before
analysis. For OT-I cultures, single cell suspensions of splenocytes were incubated for 48 hr in IL-2 containing media as described
above in the presence of SIINFEKL or SIIQFEKL peptide as indicated. For blockade of B7.1-B7.2 mediated CD28 costimulation cul-
tures were supplemented with 1 mg/ml CTLA4-Ig or human Fc-Ig control (BioXcell) before the addition of peptides.
Metabolic phenotyping
Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were measured using the Seahorse XFe bioanalyzer.
2 x105 T cells per well (R3 wells per sample) were spun onto poly-D-lysine coated seahorse 96 well plates and preincubated at
37C for a minimum of 45 min in the absence of CO2. For long assays (> 8hrs) after activation of TN or TM cells, XF media was sup-
plemented with 25mM glucose and 100 U/ml hrIL-2 (Peprotech). For activation of TN or TM cells, aCD3 ± CD28 coated beads were
used at 1:1 ratio of beads:T cell. OCR and ECARweremeasured under basal conditions, after activation, after restimulation, and after
the addition of the following drugs: 1 mM oligomycin, 1.5 mM flurorcarbonyl cynade phenylhydrazon (FCCP), 200 mM etomoxir, and
100 nM rotenone + 1 mM antimycin A (all Sigma) as indicated. Measurements were taken using a 96 well Extracellular Flux Analyzer
(SeahorseBioscience). Real-time analysis of extracellular oxygen and pH during the first 48 hr of activation was conducted in a
standard humidified incubator with 5%CO2, in a 6 well plate format using a SDR SensorDish reader (PreSens) and cells plated at
1 x106 splenocytes/ml. For metabolic tracing TN cells were isolated and activated as described above in glucose or glutamine-
free media supplemented with 11 mM D-[U13C] glucose, 4mM [U13C] glutamine or 20 mM [U13C] palmitate and cultured for 24 hr.
Cells were washed with ice cold 0.9% w/v NaCl buffer and Metabolites were extracted twice with hot ethanol (70%) and analyzed
by gc mass spectrometry (GCMS). Fractional contribution from exogenous substrates was calculated as described previously
(Buescher et al., 2015).
Flow cytometry
Fluorochrome-conjugatemonoclonal antibodieswerepurchased fromeBioscience,BDBioscience, or Life Technologies.Stainingwas
performed in 1% FBS/PBS for 30 min on ice, dead cells were excluded with the LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Thermo
scientific). OVA-specific CD8+ T cells from blood were quantified after bed blood cell lysis, by direct staining with H2-kbOVA257-264
(KbOVA) MHC-peptide tetramers. For intracellular cytokine staining cells were reactivated with aCD3/28 overnight and cultured in
the presence of Brefeldin A for 5 hr prior to fixation using Cytofix Cytoperm (BDBioscience). For determination of exogenous palmitate
uptake, cells were incubated with Bodipy conjugated palmitate (Bodipy FL C16; Life Technologies) 30min at 37
C prior to analysis. To
assay glucose uptake, 100nM2NBDGwas added for 2min at 37Cafter which the cells were cooled on ice and analyzed. (All reagents
were used according to the manufacturers recommendation). Cpt1a primary antibody staining (Proteintech Group Cat# 15184-1-AP
RRID:AB_2084676)wasdetectedusingAlexaFluor-647or 421anti-rabbit secondary antibody (Life technologies).Cellswereanalyzed
using LSR Fortessa flow cytometers (BDBiosciences) and data were processed using FlowJo software (FlowJo).
Confocal and Electron Microscopy imaging
Spinning disk confocal and EM imaging was performed as described previously (Buck et al., 2016). Cells were activated as indicated
and transferred to glass bottom dishes (MatTek) coated with fibronectin (Sigma) in complete medium containing IL-2 or IL-15 using a
Zeiss spinning disk confocal with an Evolve (EMCCD) camera. Cells were kept in a humidified incubation chamber at 37C with
5% CO2 during image collection. Confocal imaging was analyzed using Imaris imaging software. For Electron Microscope imaging
2 3 106 T cells were fixed in 2.5% glutaraldehyde in 100 mM sodium cocodylate, washed in cocodylate buffer. After dehydration
samples were embedded in Eponate 12 resin (Ted Pella) and sections were cut. Images were acquired using a JOEL 1200 EX trans-
mission electronmicroscopewith an ATMPdigital camera (Figures 2C and 3E) (AdvancedMicroscopy Techniques) or a FEI Tecnai 12
Transmission electron microscope equipped with a TIETZ digital camera (Figures 5J, S2C, and S3G). Cristae width was measured
using ImageJ software and averaged over 15 independent images, acquisition of EMmicrographs andmeasurements of max cristae
width displayed in Figures 2C, 2D, 3E, and 3F were performed blinded. Previously acquired EM images were used tomeasure cristae
width in ex vivo and in vitro generated TN, TE, and TM cells (Buck et al., 2016).e3 Cell 171, 385–397.e1–e4, October 5, 2017
Western Blotting
For western blot analysis cells were washed with ice cold PBS and lysed in 1 x Cell Signaling lysis buffer (20 mM Tris-HCl, [pH 7.5],
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM b- glycerophosphate, 1 mM
Na3VO4, 1 mg/mL leupeptin (Cell Signaling Technologies) supplemented with 1 mM PMSF. Samples were frozen and thawed 3 times
followed by centrifugation at 20,000 x g for 10 min at 4C. Cleared protein lysate was denatured with LDS loading buffer for 10 min at
70C, and loaded on precast 4% to 12% bis-tris protein gels (Life Technologies). Proteins were transferred onto nitrocellulose mem-
branes using the iBLOT 2 system (Life Technologies) following the manufacturer’s protocols. Membranes were blocked with 5%w/v
milk and 0.1% Tween-20 in TBS and incubated with the appropriate antibodies in 5%w/v BSA in TBSwith 0.1% Tween-20 overnight
at 4C. The following antibodies were used: anti- Cpt1a (Proteintech Group Cat#15184-1-AP RRID: AB_2084676), anti-TXNIP
(Cat#14715), -GAPDH (Cat#5174P) (Cell Signaling Technologies). All primary antibody incubations were followed by incubation
with secondary HRP- conjugated antibody (Pierce) in 5% milk and 0.1% Tween-20 in TBS and visualized using SuperSignal West
Pico or femto Chemiluminescent Substrate (Pierce) on Biomax MR film (Kodak). Optical density of the signals on film was quantified
using grayscale measurements in ImageJ software (NIH) and converted to fold change.
miRNA analysis
miRNA analysis was performed using the TaqMan MicroRNA Cells-to-CT Kit (Life Technologies) according to the manufacturers
recommendation. Briefly, 100K cells were collected and washed in ice cold PBS followed by resuspension in lysis buffer. 5 mL lysate
was used to generate miRNA-specific RT fragments, and miRNA expression was detected using the miR33 detection kit (Life Tech-
nologies Cat# 4427975, assay ID 002135). Relative miRNA expression levels were normalized to Hprt (Life Technologies assay ID
Mm03024075_m1).
siRNA delivery
For siRNA transfection of naive T cells we used the smartpool accell siRNA for murine Cpt1a (GE Dharmacon Cat# E-042456-00-
0005) according to the manufacturers recommendations with minor modifications. To ensure TN survival, overnight cultures in Accell
delivery medium (Cat# B-005000) were supplemented with 1% dialyzed fetal calf serum (GIBCO) and IL-7 at 10U/ml in medium.
shRNA delivery
TN cells or TE cells were transducedwith control (Luciferase-shRNA) or Cpt1a-shRNA expressing retrovirus at an estimatedMOI of 10
for the TN and 3 for the TE cells by centrifugation for 90 min (1000 x G) in the presence of polybrene (8mg/ml). To ensure more efficient
delivery of retrovirus, TN cells were cultured in media supplemented with IL-7 for 36 hr prior to infection to induce homeostatic
proliferation.
Chimeric antigen receptor (CAR) T cell generation
PBMCs were isolated from buffy coats by Pancoll (Pan Biotech) density gradient centrifugation. The untouched CD8 positive T cells
were purified from PBMC using CD8+ T Cell Isolation Kit (Miltenyi Biotec, Cat# 130-096-495). CAR construct transfections were per-
formed as described previously (Zhu et al., 2015). 10 mg AC133/CD133-CAR piggyBac transposon vector and 5 mg Super PiggyBac
Transposase (System Biosciences) plasmid were used to transfect 20 million T cells in one nucleofection reaction using a human
T cell nucleofector kit (VPA-1002, Lonza). After electroporation cells were rested overnight and then activated on the EL4 lymphoma
cell line expressing exogenous CD133.
(anti)miR electroporations
TN cells were electroporated with 3 pMol (Anti)miR oligonucleotide (Cat#MC12410/mir33-5p; Cat#AM12410/Antimir33-5p Life Tech-
nologies) in primary cell buffer 3 using the Nucleofector X unit (Lonza) according to the manufacturers recommendations. 8 hr post
electroporation miR-containing cells were activated ± aCD28. 24 hr after activation cells were fixed and stained for Cpt1a expression
by flow cytometry. For long term cultures, cells were electroporated with (anti)miR oligonucleotides in the presence of a GFP expres-
sion vector (Lonza). 24 hr after electroporation cells were sorted for GFP expression, activated with aCD3, and cultured like in Fig-
ure 1E. Cells were restimulated using aCD3/28 to assess ability to produce cytokine.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using prism 6 software (Graph pad) and results are represented as mean ± SEM, unless otherwise
indicated. Comparisons for two groups were calculated using unpaired two-tailed Student’s t tests, comparisons of more than two
groups were calculated using one-way ANOVA with Bonferroni’s multiple comparison tests. We observed normal distribution and no
difference in variance between groups in individual comparisons. Selection of sample size was based on extensive experience with
metabolic assays. The sample size for the in vivo tumor experiments shown in Figure 4 were based on previous experience with the
tumor cell line and associated transgenic T cell responses.Cell 171, 385–397.e1–e4, October 5, 2017 e4
Supplemental Figures
Figure S1. TE and TM Cells Generated ±aCD28 Display Similar Surface Marker Expression and Viability and SRC Early after Activation Is
Dependent on CD28 Signals, Independent of Strength of Signal by the TCR, Related to Figure 1
(A) Flow cytometric analysis of 2NBDG uptake during activation of cells activated with aCD3 ± aCD28.
(B) Seahorse assay showing oxygen consumption after consecutive injection of activator beads, Oligomycin, FCCP (F), and Rotenone and Antimycin (R+A) (n = 3).
(C) ATP assay run on 105 cells activated ± aCD28 at 8 hr after activation (n = 6).
(D) Histograms depicting CD44 and CD62L expression post activation. Top panels represent TE cells, bottom panels TM cells, blue histograms represent aCD3
priming, black histograms aCD3/28. Representative of > 3 independent experiments.
(E) 7-AAD staining showed no difference in viability between in vitro TM cells generated ± aCD28.
(F) TM cells generated as in Figure 1Bwere restimulated with aCD3/28 beads and IL-2. ECARwas followed for 8 hr andmaximal glycolytic capacity was assessed
by sequential treatment with Oligomycin (Oligo), FCCP, Rotenone and Antimycin (R+A).
(G) Seahorse plots of TE cells under AGR conditions, where SRC is only present in cells that received CD28 mediated costimulation. (H) Averaged bar graphs of 2
Independent experiments depicting SRC during AGR in TE cells initially stimulated ± aCD28.
(I) 7-AAD staining showed no difference in viability between in vitro TE cells generated ± aCD28 in normal glucose or during AGR. Bar graphs depict mean ± SEM.
(legend continued on next page)
(J) Splenocytes from OTI mice were activated with high-affinity peptide (SII(N)FEKL) or low-affinity peptide (SII(Q)FEKL) and oxygen concentration and pH of
extracellular media was measured during the first 48h after activation. Costimulation was blocked using CTLA4-Ig (n = 2). Blocking costimulation via CD28 with
CTLA4-Ig inhibits oxygen consumption in cells activated with high and low-affinity peptides, although the effect is more marked in cells activated with the high-
affinity peptide. These data indicate that CD28 has the greatest effect on oxygen consumption of cells activated with stronger TCR stimuli, rather than boosting
activation in cells activated with weaker stimuli. The data showing pH, suggest the same is true for aerobic glycolysis.
(K) Dilution series of aCD28 (mg/ml) during activation (n = 3) * = p < 0.05 (unpaired t test).
(L) T cell receptor beta (TCR-b) expression during activation (n = 3).



















































Figure S2. Imaris Surface Rendering as a Quantifier for Mitochondrial Sphericity, Related to Figures 2 and 3
Imaris software was used to quantify mitochondrial sphericity through surface rendering of the GFP signal localizing to the mitochondria. A surface to volume
algorithm was used to determine sphericity in images obtained from cells activated with aCD3 ± aCD28 at different time points after activation.
(A) Shown are representative images at 8 hr after activation of TE cells activated with aCD3 ± aCD28. Color scheme depicts sphericity as binned in Figures 2A, 2B
and 3D. Elongated mitochondria are Blue / low sphericity (0), round mitochondria are Red / high sphericity (1). Scale bar 5 mm.
(B) dot plots representing individual measurements ofmitochondria per group. High sphericity, Round (1) to low sphericity, elongated (0) depicted isMean ±SEM,
***p < 0,001 by comparing two groups with two tailed Student’s t test.
(C) High resolution EMmicrographs of CD8 T cells stimulated with aCD3 ± aCD28. Representative images of cells 8 hr after activation, TE cells and IL-15 TM cells
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Figure S3. CD28-Mediated SRC andMitochondrial Remodeling duringMetabolic Stress Is Dependent on Cpt1a Function, Related to Figures
3 and 4
(A) siRNA knock down efficiency in TN cells before activation (n = 3).
(B) Activation of cells generated in (A). for 8 hr, followed by injection of Oligomycin and FCCP. Graphs represent mean ± SEM of three biological replicates.
**p < 0.01.
(C) Bar graphs depicting relative bodipy-labeled palmitate uptake at 8 and 24 hr after activation ± aCD28. No differences between activation conditions were
observed (n = 4).
(D) Seahorse plot of ex vivo TM cells isolated from CD80/86
/ mice showing ETO injection (same experiment as shown in Figure 1C).
(E) TN cells isolated from 3 mice were transduced with retrovirus expression Cpt1a or Luciferase shRNA, LUC-sh. 48 hr after transduction cells were activated and
cultured as in Figure 1B. Sorted GFP+ TM cells were reactivated with aCD3/28 and assayed for the production of IFN-g. Histograms depict n = 3 biological replicates.
(legend continued on next page)
(F) Cpt1a-sh retrovirus was used to transduce TE cells to validate knockdown (n = 2). *p < 0.05 by two tailed Student’s t test.
(G) EM images of cells primed with aCD3/CD28 ± ETO. (H) Maximal cristae width of WT and OPATg naive CD8 T cells activated for 8 hr with aCD3 ± aCD28. Bar
graph depicts mean ± SEM of maximum cristae width in arbitrary units, measured from 50 images from each group using Fiji/ImageJ software.
(A, C, D, and F) Data shown as mean ± SEM, representative of R3 separate experiments. Statistical comparisons for two groups were calculated by using
unpaired two-tailed Student’s t test, **p < 0.01; *p < 0.05.
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Figure S4. CD28 Costimulation Increased Cpt1a-Dependent Allocation of Palmitate Carbons to the TCA Cycle, Related to Figures 3 and 4
(A and B) (A) Activation with aCD3 ± aCD28 does not alter allocation of carbons from Glucose (B) or Glutamine.
(C) CD28 signals increase carbon allocation from palmitate to TCA intermediates at 24 hr after activation. **p < 0.01.
(D) Schematic highlighting flux patterns of the metabolites shown in (A)–(C).
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Figure S5. CD28 Downstream Signals Suppress TXNIP in Murine and Human CD8+ T Cells, which Leads to Elevated Levels of Cpt1a, Related
to Figure 5
(A) Top 10 differentially expressed genes 24 hr after activation of CD4+ T cells. Log fold change between activationwith aCD3 ± aCD28 (n = 4) ranked on p value as
assessed by GEO2R (Analysis from data in Esensten et al., 2016).
(B) Western blot analysis at 48 hr after activation with aCD3 ± CD28. Signals shown from isolated lanes all developed on a single western blot.
(C) CD28 signals restrain TXNIP expression in human CD8+ T cells 24 hr after activation. Histograms reflect densitometry of TXNIP bands normalized to GAPDH
bands from the same sample. Western blots performed on samples from three healthy donors.
(D) Flow cytometric analysis of CPT1A expression in human T cells from 2 healthy donors 24 hr after activation (independent repeat experiment from data shown
in Figure 5D).
(E) Ratio of CPT1A and TXNIP protein expression levels 24 hr after activation. N = 3 healthy human controls.
(F) Flow cytometric analysis of CPT1A expression levels in CAR T cells after activation on target tumor cells. Adding soluble aCD28 enhances the expression of
CPT1A in 1st generation CAR T cells.
(D and E) Data shown as mean ± SEM, representative ofR3 separate experiments.
